acid (ASP-AMP), cis-2,3-piperidinedicarboxylic acid (cis-PDA), and y-o-glutamylaminomethylsulphonic acid (GAMS) were tested for their ability to produce a phencyclidine (PCP)-like catalepsy in pigeons when administered intracerebroventricularly. Each of the antagonists produced catalepsy, although L-APS, and the non-selective antagonists GAMS and cis-PDA, produced the effect only at toxic doses. The rank order of potency to produce catalepsy was API > D-AP5 > D,L-APS > cis-PDA > ASP-AMP > AP4 z L-AP5 > GAMS; there was a strong positive correlation between this rank order of potency in viuo and the potency order of these compounds in vitro as NMDA antagonists. The antagonists did not displace significant amounts of [3H]N-[I-(2-thienyl)cyclohexyl]piperidine (a congener of phencyclidine) from its recognition site in the brain of pigeon. Thus, the PCP-like catalepsy that is produced by the excitatory neurotransmission at NMDA-preferring receptors that are distinct from, but related to, PCP receptors. The results strongly support the hypothesis that a reduction of neurotransmission at excitatory synapses, utilizing NMDApreferring receptors, may underlie catalepsy in pigeons induced by PCP.
(NMDA), kainate, or quisqualate (Watkins and Evans, 1981) . The NMDApreferring receptor is the most extensively characterized of the three types of receptor, because of the availability of potent and highly selective NMDA antagonists, such as D,L-2-amino-5-phosphonovalerate (D,L-APS).
Phencyclidine (PCP) and PCP-like drugs selectively antagonize excitation of neurons induced by NMDA with little effect on the equivalent excitation induced by kainate or quisqualate (Anis, Berry, Burton and Lodge, 1983) . Therefore, certain behavioral effects of PCP may be mediated by a reduction of neurotransmission at excitatory synapses utilizing NMDApreferring receptors. If this hypothesis is correct, drugs that are known to antagonize the effects of NMDA should produce PCP-like behavioral effects. Because of its pharmacological specificity and stereoselectivity, the catalepsy test in pigeons provides a *Portions of these data were presented by W.K. at the meeting of the Federation bf American Societies for Experimental Biology, St Louis, MO. (Mudar, Koek, Jacobson and Woods, 1986 ).
suitable procedure for studying PCP-like behavioral activity of compounds (Koek, Woods, Rice, Jacobson, Huguenin and Burke, 1984) .
Recently,
was found to produce PCP-like catalespy in pigeons, lending support to this hypothesis of mechanism of action for PCP (Koek, Kleer, Mudar and Woods, 1986a) . The aims of the present study were: (1) to investigate whether other excitatory amino acid antagonists produced PCP-like catalepsy in pigeons; (2) to investigate whether their ability to induce PCP-like catalepsy was positively correlated with their rank order of potency as NMDA antagonists; and (3) to study whether the excitatory amino acid antagonists interacted with PCP-receptors in the brain of the pigeon.
Catalepsy assay

METHODS
White Cameaux pigeons were used. They were housed individually with food, grit and water freely available.
A chronic, indwelling guide cannula was implanted in each pigeon with the tip inserted directly into the lateral ventricle; the patency of the cannula was assessed by a radiographic method (France, Adams and Woods, 1985) following surgery and once every month afterwards.
Drugs were injected intracerebroventricularly (i.c.v.) in a volume of 10 PI/pigeon, during a I-min period. The injection cannula was removed from the guide cannula 30 set after the end of the injection period. The presence or absence of catalespy (defined as loss of righting, without head-drop and without eye closure; Koek et al., Koek, Woods, Jacobson, Rice and Lessor, 1986b) was assessed at successive time intervals after the injection. Each dose was tested in 556 pigeons that were selected at random from the group of cannulated pigeons (n =40). Only data obtained from tests that were both preceded and followed by a positive X-ray were included in the analysis. Tests with drugs were separated by at least 48 hr.
Binding assay for TCP
Whole brain (minus cerebellum) from White Carneaux pigeons was removed and frozen immediately. Frozen brains was thawed and homogenized in 70 vol of 5 mM Tris-HCl buffer (pH 7.4) with a Brinkman polytron (setting 6, 20 set). The homogenates were centrifuged three times at 20,000 g for 20 min at 5°C with intervening resuspensions of the pellet in fresh buffer. The final pellet was resuspended in 70 vol of fresh Tris buffer and stored at 0°C.
Binding of [3H]N-l[l-(2-thienyl)cyclohexyl]piperidine (TCP) to membranes from brain was determined by incubating 900~1 of tissue (containing 0.5mg of protein), 50~1 of 5pM [3H]TCP (55.3 Ci/mmol; New England Nuclear) and 50 ~1 buffer (or a final concentration of 10 PM TCP for a determination of nonspecific binding) for 1 hr at 5°C. The reaction was terminated by rapid filtration (Brandel Cell Harvester, Gaithersburg, Maryland) through Schleicher & Schuell No. 32 filters which had been presoaked in 0.03% polylysine (Sigma, M, 150,00(r300,000) for 2 hr at 5°C. The filters were washed with two 5.0 ml aliquots of ice-cold Tris buffer and placed in counting vials containing 10 ml of Hydrofluor scintillation cocktail (National Diagnostics).
The AP4, D,L-AP5, AP7, GAMS, and cis-PDA, in concentrations of 1, 10 and lOOnM, and 1, 10, and 100 PM, were examined for their ability to inhibit the binding of [3H]TCP to recognition sites in the membranes from the brain of pigeons.
Drugs
The following drugs were used:
acid (cis-PDA) and y -D-ghrtamylaminomethylsulphonic acid (GAMS). Each was dissolved in 1.0 N NaOH, to which sterile water was added: pH 6-8. Each of the above was purchased from Tocris Chemicals (Buckhurst Hill, England), except for TCP and PCP (National Institute on Drug Abuse, Rockville, Maryland).
Catalepsy assay
RESULTS
Each of the excitatory amino acid antagonists induced PCP-like catalepsy in pigeons at 15 min after intracerebroventricular administration (Fig. 1) . For all drugs, except L-AP5, the straight lines shown in Figure 1 provided a sufficient fit (Chi-square test; P > 0.05) to the data. Further, these lines did not deviate significantly from parallel (slope-ratio test; P > 0.05). The D-(-)-AP5 was about 24 times more potent than L-( +)-AP5 in producing catalepsy (ED,,: 0.21 and 5pmol, respectively) and was nearly equipotent to the racemate, D,L-AP5 (ED, , : 0.22, umol) . Unlike the racemate or the D-isomer of AP5, L-( +)-AP5 (top panel, Fig. 1 ) failed to induce catalepsy in all pigeons at the lowest dose tested (i.e. 5.6pmol; a dose that was lethal in 40% of the pigeons). As a result, the ED,, dose of L-(+)-AP5 could not be calculated by means of the method of Litchfield and Wilcoxon (1949) but was calculated by interpolation.
The congeners of D,L-AP5, AP4 and AP7, also induced catalepsy, as did the dipeptide ASP-AMP (Fig. 1, middle panel) ; the potency order of these compounds to induce catalespy was AP7 > AP5 > ASP-AMP > AP4. In addition, catalepsy was induced by intracerebroventricuiar administration of the non-selective antagonists cis-PDA and GAMS. However, this effect was produced only at lethal doses; 1 .O pmol of cis-PDA was lethal in 40% of the animals tested, as was 18.0 pmol of GAMS. Compared to D,L-APS, the potency order of these compounds to induce catalespy was D,L-AP5 > cis-PDA > GAMS (Fig. 1, lower panel) .
The mean duration of catalepsy that was induced by the excitatory amino acid antagonists at the largest doses was not significantly different (F[6,27] = 1.19. P > 0.2; one-way analysis of variance, Keppel, 1973) . The mean duration of catalepsy (+ 1 SEM), averaged for the drugs, was 79.4 f 12.9 min. Table 1 shows the ED,, values of the excitatory amino acid antagonists to produce PCP-like catalepsy. A statistically significant and positive correlation of 0.81 (Spearman rank correlation coefficient; Siegel, 1956) was found between the order of potency of the antagonists to produce catalepsy and their order of potency in blocking the excitatory effects of NMDA on motor neurons of the frog. Further, a significant positive correlation of 0.79 was found between the order of potency of the antagonists to produce PCP-like catalepsy and the order of potency of these compounds to inhibit the binding of ['HID-AP5 in brain of the rat. Finally, the order of potency of the antagonists to produce catalepsy and their order of potency in blocking the effects of kainate and of quisqualate on motor neurons of the frog were correlated negatively.
Binding assay for TCP
In the binding assay, AP4, D,L-APS, API, GAMS, and cis-PDA did not displace significant amounts of [3H]TCP from its binding sites in membranes from the brain of the pigeon, neither when tested in the effective concentration range of TCP (E& = 38 nM) and PCP (EC,, = 129 nM), nor when tested in the micromolar range (data not shown). Even in a concentration of 100 PM, AP4, AP5, API, cis-PDA and GAMS displaced less than 50% [3H]TCP.
DISCUSSION
Catalepsy in pigeons, an effect that is produced exclusively by PCP-like agents (e.g. Koek et al., 1984) , was shown to be also produced by intracerebroventricular administration of excitatory amino acid antagonists (i.e. D,L-AP5, D-(-) and L-(+)-APS, AP4, AP7, ASP-AMP, cis-PDA and GAMS).
Likewise, catalepsy is produced by PCP-like compounds that stereoselectively displace PCP from recognition sites (e.g. Koek et al., 1984) . The APS-induced catalepsy was stereoselectively produced, as shown by the observation that D-( -)-AP5 was more potent than L-( +)-AP5 in producing catalepsy. Further, whereas D-( -)-AP5 produced catalepsy in all the pigeons tested, L-( +)-AP5 failed to do so when tested in up to lethal doses. If the ability to induce catalepsy in pigeons resides almost exclusively in the D-isomer of AP5, it would be expected that D-AP5 would be twice as potent as the racemate. The absence of a potency difference between D-(-)-AP5 and D,L-AP5, that was observed in the present study, may perhaps be related to a degree of variability in the behavioral data that precluded the detection of small differences in potency.
On the basis of the relative potencies of the excitatory amino acid antagonists in blocking the effects of NMDA on motor neurons of the frog (Jones, Smith and Watkins. 1984) and in inhibiting the binding of the highly selective NMDA antagonist ['HID-(-)-AP5 in brain of the rat (Olverman, Jones and Watkins, 1984) , a potency order of D-(-)-APS > AP7 > D,L -AP5 > ASP -AMP > cis -PDA > GAMS > AP4 in producing PCP-like catalepsy can be predicted for these compounds if their catalepsyinducing effects are dependent upon antagonism at NMDA-preferring receptors. Indeed, the rank order of potency of these compounds to produce catalepsy was found to be in good agreement with the rank order of potency as predicted from electrophysiological and binding data; given this strong positive correlation, a negative relationship between the rank order of potency to induce catalepsy and the rank order of potency to antagonize the electrophysiological effects of kainate~quisqualate may be expected, because the compounds selected for study resulted from attempts to develop selective NMDA antagonists and selective non-NMDA antagonists.
The significant correlation between the potencies of the excitatory amino acid antagonists to produce catalepsy and their potencies as NMDA antagonists suggests that the catalepsy produced by these compounds may result from reduced excitatory neurotransmission at NMDA-preferring receptors. These receptors may be distinct from PCP receptors, because the antagonists failed to displace significant amounts of labelled TCP from binding sites for PCP in brain of pigeon (this study) and because the congener of PCP ketamine has been reported to be inactive at displacing APS (Olverman and Watkins, cited in Martin and Lodge, 1985) . However, the NMDA-preferring receptor and the PCP receptor may form a receptor complex similar to that demon-strated for the benzodiazepines and y -aminobutyric acid-(GABA) (Loo, Braunwalder, Lehmann and Williams, 1986a ). Since the experiments described here were conducted, Loo, Braunwalder, Lehmann and Williams (1986b) 
